Novo, Lilly Stocks Rise. Weight-Loss Drugs Reduce Risk of Alzheimer's, Study Shows. - Barron's

1. Study shows GLP-1 drugs reduce Alzheimer's risk by 12%. 2. Novo's Semaglutide leads in market for diabetes and weight-loss. 3. Expanded uses for GLP-1 could boost sales and profitability. 4. Insurers may soon cover GLP-1 drugs, enhancing access. 5. Novo faces competition despite current lead in weight-loss therapies.